Claims

~~1. Use of methazolamide in the manufacture of a medicament for decreasing elevated serum alanine transaminase (ALT) levels in a patient, wherein the medicament is for administration of methazolamide at a dosage rate in the range of less than 100 mg to about 80 mg per day.~~

~~2~~1. Use of methazolamide in the manufacture of a medicament for treating or preventing liver dysfunction in a patient, wherein the medicament is for administration of methazolamide at a dosage rate ~~in the range of less than 100 mg to about~~ 80 mg to less than 100 mg per day.

~~3. Use of methazolamide in the manufacture of a medicament for reducing elevated liver lipid levels in patient, wherein the medicament is for administration of methazolamide at a dosage rate in the range of less than 100 mg to about 80 mg per day.~~

~~4~~2. Use of methazolamide in the manufacture of a medicament for treating or preventing non-alcoholic fatty liver (NAFL), wherein the medicament is for administration of methazolamide at a dosage rate in the range of ~~less than 100 mg to about~~ 80 mg to less than 100 mg per day.

~~5~~3. Use of methazolamide in the manufacture of a medicament for treating or preventing non-alcoholic steatohepatitis (NASH), wherein the medicament is for administration of methazolamide at a dosage rate in the range of ~~less than 100 mg to about~~ 80 mg to less than 100 mg per day.

~~6~~4. The use according to any one of claims 1~~-5~~-3, wherein the medicament is for administration of methazolamide at a dosage rate of about 90, 85 or 80 mg per day.

~~7~~5. The use according to claim ~~6~~4, wherein the medicament is for administration at a dosage rate of about 80 mg per day by administration of a dosage of about 40 mg twice daily.

~~8~~6. The use according to any one of claims 1~~-7~~5, wherein the patient is also pre-diabetic or diabetic.

97. The use according to any one of claims 1-8-6, wherein the patient has an HbA_{1c} level of ≥6.5%.

108. The use according to any one of claims 1-97 wherein the methazolamide is administered in combination with an anti-diabetic agent.,

119. The use according to claim 10-8 wherein the anti-diabetic agent is metformin or a pharmaceutically acceptable salt thereof.

1210. A composition, comprising:

methazolamide,

metformin, and

one or more pharmaceutically acceptable additives,

wherein the weight ratio of methazolamide to metformin in the composition is 1:6.25 – 1:56.25.

1311. The composition of claim 1210, wherein the methazolamide is present in an amount of 80 mg.

1412. The composition of claim 12-10 or claim 1311, wherein the metformin is present in an amount of 500 mg – 4,500 mg.

1513. The composition of any one of claims 12-1410-12, wherein the metformin is present in an amount selected from 1,250 mg and 1,545 mg.

1614. The composition of any one of claims 12-1410-12, wherein the metformin is present in an amount selected from 500, 750, 850 and 1,000 mg.

1715. The composition of any one of claims 12-1610-14, wherein the metformin is a pharmaceutically acceptable salt of metformin.

1816. The composition of claim 1715, wherein the metformin is metformin hydrochloride.

~~19~~17. The composition of any one of claims ~~12-18~~10-16, wherein the methazolamide and metformin are formulated together as an intimate composition.

~~20~~18. A combination, comprising:

methazolamide, and

metformin,

wherein the weight ratio of methazolamide to metformin in the combination is 1:6.25 – 1:56.25.

~~21~~19. The combination of claim ~~20~~18, wherein the methazolamide is present in an amount of 80 mg.

~~22~~20. The combination of claim ~~20-18~~ or claim ~~21~~19, wherein the metformin is present in an amount of 500 mg – 4,500 mg.

~~23~~21. The combination of any one of claims ~~20-22~~18-20, wherein the metformin is present in an amount selected from 1,250 mg and 1,545 mg.

~~24~~22. The combination of any one of claims ~~20-22~~18-20, wherein the metformin is present in an amount selected from 500, 750, 850 and 1,000 mg.

~~25~~23. The combination of any one of claims ~~20-24~~18-22, wherein the metformin is a pharmaceutically acceptable salt of metformin.

~~26~~24. The combination of claim ~~25—23~~ wherein the metformin is metformin hydrochloride.

~~27~~25. A composition, comprising:

methazolamide in an amount of 1 mg – 90 mg, and

metformin in an amount of 50 mg – 1,000 mg.

~~28~~26. The composition of claim ~~27~~25, wherein the methazolamide and metformin are formulated together as an intimate composition.

2927. The composition of claim 27-25 or claim 2826, further comprising one or more pharmaceutically acceptable additives.

3028. The composition of any one of claims 27-29, wherein the amount of methazolamide is selected from 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 75 mg, 80 mg and 90 mg.

3129. The composition of any one of claims 27-3025-27, wherein the amount of metformin is selected from 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 500 mg, 750 mg, 850 mg and 1,000 mg.

3230. Use of methazolamide in the manufacture of a medicament for treating NASH.

~~33. The use according to claim 32 wherein the methazolamide is for administration at a dosage rate of less than 100 mg to about 80 mg per day.~~

34.31 The use according to claim 32 or 3330, wherein the methazolamide is for administration at a dosage rate of about 80 mg per day by administration of about 40 mg twice daily.

3532. The use according to ~~any one of claims 32-34~~claim 30 or claim 31, wherein the methazolamide is for administration in combination with an anti-diabetic agent.

3633. The use according to claim 35-32 wherein the anti-diabetic agent is metformin or a pharmaceutically acceptable salt thereof.

3734. The use according to claim 36-33 wherein the metformin is metformin hydrochloride.